{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:21:09Z","timestamp":1793845269801,"version":"4.6.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clml.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:02:48Z","timestamp":1772856168000},"page":"357-365.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prophylactic Immunoglobulin Supplementation for Infection Prevention in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1452-039X","authenticated-orcid":false,"given":"Akihiro","family":"Miyashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3372-010X","authenticated-orcid":false,"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Takaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0224-7501","authenticated-orcid":false,"given":"Yoshito","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.03.002_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1098326","article-title":"Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: a systematic literature review","volume":"13","author":"Jolles","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.002_bib0002","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1186\/s12885-021-08451-x","article-title":"Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019","volume":"21","author":"Balmaceda","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.03.002_bib0003","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-024-01107-6","article-title":"IgG replacement in multiple myeloma","volume":"14","author":"Wonnaparhown","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2026.03.002_bib0004","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"issue":"23","key":"10.1016\/j.clml.2026.03.002_bib0005","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2026.03.002_bib0006","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjh.17235","article-title":"Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021","volume":"193","author":"Demel","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.03.002_bib0007","article-title":"Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs","author":"Jelinek","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.03.002_bib0008","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.03.002_bib0009","article-title":"Invasive fungal infections in patients with multiple myeloma: a possible growing problem in hematology and infectious diseases","volume":"11","author":"Valkovic","year":"2024","journal-title":"Ther Adv Infect Dis"},{"issue":"3","key":"10.1016\/j.clml.2026.03.002_bib0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.20158","article-title":"Pneumococcemia as the presenting feature of multiple myeloma","volume":"77","author":"Costa","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.03.002_bib0011","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fimmu.2014.00257","article-title":"Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"5","author":"Tete","year":"2014","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.clml.2026.03.002_bib0012","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2026.03.002_bib0013","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1586\/14787210.2015.1083858","article-title":"Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization","volume":"13","author":"Teh","year":"2015","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"1","key":"10.1016\/j.clml.2026.03.002_bib0014","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.clml.2026.03.002_bib0015","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1093\/cid\/cis298","article-title":"Baseline platelet count and creatinine clearance rate predict the outcome of neutropenia-related invasive aspergillosis","volume":"54","author":"Nou\u00e9r","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.clml.2026.03.002_bib0016","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.03.002_bib0017","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.intimp.2017.09.005","article-title":"Immunoglobulin replacement therapy in primary and secondary antibody deficiency: the correct clinical approach","volume":"52","author":"Pecoraro","year":"2017","journal-title":"Int Immunopharmacol"},{"issue":"14","key":"10.1016\/j.clml.2026.03.002_bib0018","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1056\/NEJM198810063191403","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial","volume":"319","author":"Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia","year":"1988","journal-title":"N Engl J Med"},{"issue":"8905","key":"10.1016\/j.clml.2026.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(94)90180-5","article-title":"Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple myeloma","volume":"343","author":"Chapel","year":"1994","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2026.03.002_bib0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2026.03.002_bib0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2026.03.002_bib0022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.clml.2026.03.002_bib0023","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2026.03.002_bib0024","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.clml.2026.03.002_bib0025","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jha2.938","article-title":"Variation in immunoglobulin use and impact on survival in myeloma","volume":"5","author":"Chai","year":"2024","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.clml.2026.03.002_bib0026","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2026.03.002_bib0027","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of intravenous immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.03.002_bib0028","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin Immunol"},{"issue":"5","key":"10.1016\/j.clml.2026.03.002_bib0029","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/tid.12424","article-title":"Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma","volume":"17","author":"Park","year":"2015","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"10.1016\/j.clml.2026.03.002_bib0030","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00277-011-1275-3","article-title":"Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications","volume":"90","author":"Blombery","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2026.03.002_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/10781552251347240","article-title":"The utility of intravenous immunoglobulin infection prophylaxis in patients on anti-CD38 therapies","author":"Konieczny","year":"2025","journal-title":"J Oncol Pharm Pract."},{"issue":"6","key":"10.1016\/j.clml.2026.03.002_bib0032","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.clml.2026.03.002_bib0033","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.medcli.2023.10.005","article-title":"Secondary hypogammaglobulinemia in adults \u2013 a large retrospective cohort study","volume":"162","author":"Angarola","year":"2024","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.clml.2026.03.002_bib0034","article-title":"Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Latin America","volume":"8","author":"Bove","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.03.002_bib0035","doi-asserted-by":"crossref","first-page":"6923","DOI":"10.4049\/jimmunol.180.10.6923","article-title":"Blockade of virus infection by human CD4+ T cells via a cytokine relay network","volume":"180","author":"Davis","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.002_bib0036","doi-asserted-by":"crossref","first-page":"616","DOI":"10.4049\/jimmunol.1200924","article-title":"Innate instruction of CD4+ T cell immunity in respiratory bacterial infection","volume":"189","author":"Trunk","year":"2012","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.002_bib0037","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1056\/NEJM200007133430207","article-title":"The immune system. Second of two parts","volume":"343","author":"Delves","year":"2000","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2026.03.002_bib0038","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2026.03.002_bib0039","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70091","article-title":"The real world impact of immunoglobulin replacement therapy on severe bacterial infection for patients with hypogammaglobulinemia secondary to hematologic malignancies: a Japanese claims database study","volume":"6","author":"Mihara","year":"2025","journal-title":"EJHaem"},{"issue":"15","key":"10.1016\/j.clml.2026.03.002_bib0040","doi-asserted-by":"crossref","first-page":":3780-3789","DOI":"10.1182\/bloodadvances.2024015477","article-title":"Real-world effectiveness of immunoglobulin replacement for hypogammaglobulinemia and infections in multiple myeloma","volume":"9","author":"O\u2019Donnell","year":"2025","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"10.1016\/j.clml.2026.03.002_bib0041","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e19083","article-title":"Exploring hidden risk: the prevalence of humoral immunodeficiency in patients with lymphoproliferative disorders\u2014a prospective study","volume":"43","author":"Saeed","year":"2025","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.clml.2026.03.002_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.clml.2026.03.002_bib0043","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 16","key":"10.1016\/j.clml.2026.03.002_bib0044","article-title":"Real-world comparison of anti-BCMA vs anti-GPRC5D BiTE therapy in relapsed\/refractory multiple myeloma without prior CAR-T cell exposure","volume":"43","author":"Khan","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.clml.2026.03.002_bib0045","article-title":"Comprehensive assessment of adverse event profiles associated with bispecific T cell engagers in multiple myeloma","volume":"42","author":"Golmohammadi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.03.002_bib0046","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol"},{"issue":"24","key":"10.1016\/j.clml.2026.03.002_bib0047","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.clml.2026.03.002_bib0048","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2026.03.002_bib0049","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/TP.0b013e3182911739","article-title":"Proteasome inhibition profoundly affects activated human B cells","volume":"95","author":"Mulder","year":"2013","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.clml.2026.03.002_bib0050","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.clml.2026.03.002_bib0051","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2026.03.002_bib0052","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and its implications in patients treated with Daratumumab: a single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.03.002_bib0053","doi-asserted-by":"crossref","first-page":"AB231","DOI":"10.1016\/j.jaci.2023.11.741","article-title":"Hypogammaglobulinemia and risk of infection following Daratumumab in patients with multiple myeloma","volume":"153","author":"Hong","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2026.03.002_bib0054","article-title":"Infection risks associated with daratumumab-containing regimens in multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Huang","year":"2025","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.03.002_bib0055","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a Work Group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.clml.2026.03.002_bib0056","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","article-title":"Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies","volume":"137","author":"Orange","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clml.2026.03.002_bib0057","article-title":"Investigation of early mortality in the patients with newly diagnosed multiple myeloma: insights from a real-world cohort using J-CHAEGE-MM database","author":"Tokuhira","year":"2025","journal-title":"Int J Hematol."},{"issue":"5","key":"10.1016\/j.clml.2026.03.002_bib0058","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.18324","article-title":"Predictors of early mortality in multiple myeloma: results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)","volume":"198","author":"McQuilten","year":"2022","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.002_bib0059","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.03.002_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107544","article-title":"Multiple myeloma and infections in the era of novel treatment modalities","volume":"143","author":"Akhmedov","year":"2024","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.clml.2026.03.002_bib0061","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/jamapediatrics.2021.4583","article-title":"Cost utility of lifelong immunoglobulin replacement therapy vs hematopoietic stem cell transplant to treat agammaglobulinemia","volume":"176","author":"Sun","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"2","key":"10.1016\/j.clml.2026.03.002_bib0062","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.anai.2017.11.002","article-title":"Home-based subcutaneous immunoglobulin therapy vs hospital-based intravenous immunoglobulin therapy: a prospective economic analysis","volume":"120","author":"Fu","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1\u20132","key":"10.1016\/j.clml.2026.03.002_bib0063","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.hjdsi.2016.04.004","article-title":"Home infusion: safe, clinically effective, patient preferred, and cost saving","volume":"5","author":"Polinski","year":"2017","journal-title":"Healthc (Amst)"},{"issue":"5","key":"10.1016\/j.clml.2026.03.002_bib0064","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s10875-016-0288-z","article-title":"Switching patients to home-based subcutaneous immunoglobulin: an economic evaluation of an interprofessional drug therapy management program","volume":"36","author":"Perraudin","year":"2016","journal-title":"J Clin Immunol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.002_bib0065","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jaci.2012.08.022","article-title":"Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center","volume":"131","author":"Ducruet","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.clml.2026.03.002_bib0066","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1056\/NEJM199107113250202","article-title":"Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia","volume":"325","author":"Weeks","year":"1991","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2026.03.002_bib0067","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.03.002_bib0068","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.3389\/fimmu.2018.01299","article-title":"Adverse effects of immunoglobulin therapy","volume":"9","author":"Guo","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clml.2026.03.002_bib0069","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.clml.2026.03.002_bib0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2026.03.002_bib0071","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:15:15Z","timestamp":1793607315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2152265026000662"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic Immunoglobulin Supplementation for Infection Prevention in Multiple Myeloma: An Updated Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}